Clinical Advancements in Covid-19 Treatment Options, Settle the Nerves

The corona virus pandemic has created a sense of urgency in the healthcare industry. The manner of outbreak is what has alerted researchers and healthcare professionals alike. With over 1 lac global deaths in the first four months of its outbreak, the corona virus has been deemed as one of the deadliest viruses ever to have existed. Although several measures are being taken to minimize the disease from spreading further, all eyes are now on the treatment options. In its upcoming report on the Corona virus treatment, Fortune Business Insights highlights the ongoing clinical studies associated with the treatment of the disease, with respect to drugs as well as therapeutic procedures. The report will assess ongoing activities by major pharma companies and label out companies that are on the latter phases of clinical trials.

Gilead Science’s Anti-viral ‘Remdesivir’ is Yielding Promising Results

Among the list of ongoing clinical studies, US-based Gilead Sciences has certainly caught attention from across the world. The company had initiated clinical trials for its anti-viral drug ‘Remdesivir’, stating that it had the potential to treatment viruses as severe as the corona virus. In its latest study, the company revealed that out of 56 patients in the moderate or serious stages of the disease, 36 seemed to have recovered at a faster rate, after being treated with compassionate-use of Remdesivir. The drug seemed to have speeded up the recovery processes. Although no definite conclusions have been established as of now, the surge in the company’s trade value and purchases may indeed be positive signs of what is to follow.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/covid-19-treatment-pipeline-review-2020-102661

In the Wake of Health & Economic Crisis, Major Pharma Companies are Focusing on Collaborations

The ongoing corona virus pandemic has created a huge awareness regarding its precaution measures. From trade shutdowns to operative lockdowns, state governments as well as world leaders are enforcing strict measures to curb the spread of the disease. The evident impact and seriousness of the disease has created a huge emphasis on the R&D of various treatment options. Owing to the fact that this is a global outbreak, companies from across the world are looking to go above and beyond to bring the essential drugs. As several previous clinical trials have failed, companies are looking o collaborate amongst each other, with a view to developing an efficient treatment method. A few of the major company collaborations have been highlighted below:

• Sanofi and Regeneron: The companies are currently performing several studies on a ‘Kevzara’. Early indications are that the drug has a huge potential for use in treatment of Covid-19. Kevzara has already been used in treatment of patients suffering from arthritis. It is being tested in patients who are currently hospitalized under the latter phases of the Covid-19.

Roche Pharma and the US Health and Human Service Department:

Roche Pharma, a subsidiary of F. Hoffman-La Roche Ltd announced that it will be collaborating with the US Health and Human Service Department with the hope of developing an efficient drug for the treatment of Covid-19. The ‘Acterma’ is currently under the phase-3 clinical trial. The drug is currently approved for treatment of rheumatoid arthritis and early indications are that the drug may prove helpful in speeding up recovery process for patients diagnosed with the disease.

Report Scope:

• The report will include a comprehensive overview of several products that are currently being tested for treatment of Covid-19.


• Companies that have made headway with respective drugs have been highlighted.


• Several drugs that have the potential to treat the corona virus will be briefly discussed.